AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 72 filers reported holding AMYLYX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $72,709 | -21.0% | 3,971 | -6.9% | 0.00% | -33.3% |
| Q2 2023 | $92,017 | +170301.9% | 4,266 | +135.4% | 0.00% | +50.0% |
| Q1 2023 | $54 | -22.9% | 1,812 | -4.5% | 0.00% | -33.3% |
| Q4 2022 | $70 | -99.9% | 1,898 | -37.9% | 0.00% | +200.0% |
| Q3 2022 | $86,000 | +34.4% | 3,058 | -8.4% | 0.00% | 0.0% |
| Q2 2022 | $64,000 | +540.0% | 3,340 | +369.8% | 0.00% | – |
| Q1 2022 | $10,000 | – | 711 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alpha Wave Global, LP | 853,262 | $18,404,861 | 12.06% |
| Stonepine Capital Management, LLC | 1,121,028 | $24,180,574 | 8.72% |
| GREAT POINT PARTNERS LLC | 968,795 | $20,896,908 | 4.09% |
| Ghost Tree Capital, LLC | 550,000 | $11,863,500 | 3.92% |
| Perceptive Advisors | 4,873,919 | $105,130,433 | 3.04% |
| Altium Capital Management LP | 185,000 | $3,990,450 | 3.02% |
| Boxer Capital, LLC | 2,084,000 | $44,952 | 2.08% |
| SECTORAL ASSET MANAGEMENT INC | 387,310 | $8,354,277 | 1.39% |
| AlphaCentric Advisors LLC | 108,000 | $2,329,560 | 1.29% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 680,035 | $14,668,355 | 0.80% |